Obstetrics, gynecology, Trichomoniasis, malaria
Health Checks Needed After Trichomoniasis
Mar
Trichomoniasis, a sexually transmitted infection (STI) caused by the parasite Trichomonas vaginalis, affects millions of people worldwide. While often asymptomatic, untreated trichomoniasis can lead to various health complications, including pelvic inflammatory disease, increased risk of HIV transmission, and adverse pregnancy outcomes. Proper diagnosis and treatment are crucial for managing this infection and preventing its spread.
However, receiving treatment for trichomoniasis is not the end of the journey. Post-treatment health checks are essential to ensure complete eradication of the infection, monitor for potential complications, and promote overall sexual health. This article will explore the importance of health checks after trichomoniasis, discussing the necessary tests, examinations, and preventive measures to help individuals maintain optimal reproductive and sexual well-being.
Understanding Trichomoniasis
What is Trichomoniasis?
Trichomoniasis is a common sexually transmitted infection (STI) caused by the parasite Trichomonas vaginalis. This single-celled protozoan primarily infects the urogenital tract, including the vagina, urethra, and paraurethral glands[1]. Trichomoniasis can affect both men and women, although it is more prevalent and symptomatic in women.
Symptoms of Trichomoniasis
Trichomoniasis can present with a variety of symptoms, but many infected individuals remain asymptomatic. When symptoms do occur, they typically appear within 5 to 28 days after exposure[2]. Common signs and symptoms in women include:
- Vaginal discharge with an unpleasant odor
- Genital itching or irritation
- Pain during urination or sexual intercourse
Men with trichomoniasis may experience mild urethral discharge, itching, or burning during urination. However, most infected men do not exhibit any noticeable symptoms[3].
Transmission of Trichomoniasis
Trichomoniasis is primarily transmitted through sexual contact with an infected partner. The parasite can survive in the genital tract for extended periods, allowing for easy spread during unprotected sexual activity. While less common, the infection can also be transmitted through shared sex toys or contaminated towels or clothing.
Risk Factors for Trichomoniasis
Certain factors can increase an individual’s risk of contracting trichomoniasis, including:
- Multiple sexual partners
- History of other STIs
- Unprotected sexual activity
Complications of Untreated Trichomoniasis
If left untreated, trichomoniasis can lead to various health complications. In women, the infection may cause pelvic inflammatory disease (PID), which can result in chronic pelvic pain, infertility, and ectopic pregnancy. Trichomoniasis also increases the risk of acquiring or transmitting HIV and can cause adverse pregnancy outcomes, such as preterm delivery and low birth weight[2].
Diagnosis and Treatment of Trichomoniasis
Physical Examination
When a patient presents with symptoms suggestive of trichomoniasis, a healthcare provider will perform a physical examination. In women, this may involve a pelvic exam to assess for signs of inflammation, discharge, or cervical tenderness. Men may undergo a genital examination to check for urethral discharge or irritation[4].
Laboratory Tests for Trichomoniasis
To confirm the diagnosis of trichomoniasis, laboratory tests are necessary. The most common methods include:
- Wet mount microscopy: A sample of vaginal or urethral discharge is examined under a microscope for the presence of motile trichomonads.
- Culture: Discharge samples are cultured in a specialized medium to detect the growth of Trichomonas vaginalis.
- Nucleic acid amplification tests (NAATs): These highly sensitive and specific tests detect the genetic material of the parasite[5].
Antibiotic Therapy for Trichomoniasis
Once diagnosed, trichomoniasis is treated with antibiotic therapy. The recommended first-line treatment is a single dose of oral metronidazole or tinidazole[6]. These medications are highly effective, with cure rates exceeding 90%. In cases of treatment failure or recurrence, longer courses of antibiotics may be prescribed.
| Medication | Dosage | Efficacy | |
|---|---|---|---|
| First-line | Metronidazole or Tinidazole | Single 2g oral dose | >90% cure rate |
| Alternative | Metronidazole | 500mg orally twice daily for 7 days | >90% cure rate |
Partner Notification and Treatment
Trichomoniasis is sexually transmitted, so it is crucial to inform sexual partners of the diagnosis. Partners should be evaluated and treated concurrently to prevent reinfection and further transmission. Health care providers can assist with partner notification and provide guidance on abstaining from sexual activity until treatment is complete.
Follow-up After Treatment
Follow-up testing is recommended to ensure the effectiveness of treatment and to check for reinfection. Patients should be retested within three months of treatment, preferably using NAATs[5]. If symptoms persist or recur, additional evaluation and treatment may be necessary.
Importance of Post-Treatment Health Checks
Confirming Treatment Effectiveness
While antibiotic therapy for trichomoniasis is highly effective, it is essential to confirm that the treatment has successfully eradicated the infection. Post-treatment health checks, typically involving a repeat NAATs test, can provide reassurance that the antibiotics have worked as intended. This follow-up testing is usually performed 3 to 4 weeks after completing treatment[7].
Detecting Reinfection
Trichomoniasis is sexually transmitted, and reinfection can occur if a partner has not been concurrently treated or if a treated individual engages in sexual activity with a new infected partner. Post-treatment health checks can help identify reinfection early, allowing for prompt retreatment and prevention of potential complications[8].
Monitoring for Complications
Untreated trichomoniasis can lead to various complications, particularly in women. These may include pelvic inflammatory disease, increased risk of HIV acquisition, and adverse pregnancy outcomes. Even after successful treatment, it is important to monitor for any signs or symptoms of these complications. Regular follow-up visits with a healthcare provider can help identify and address any potential issues in a timely manner.
| In Women | In Men |
|---|---|
| Pelvic inflammatory disease | Urethritis |
| Increased risk of HIV acquisition | Prostatitis |
| Adverse pregnancy outcomes | Infertility (rare) |
Promoting Sexual Health Education
Post-treatment health checks offer an opportunity for healthcare providers to educate patients about sexual health and STI prevention. This may include guidance on safer sex practices, such as consistent condom use, and the importance of regular STI testing. By empowering individuals with knowledge and resources, providers can help reduce the risk of future infections and promote overall sexual well-being.
Addressing Mental Health Concerns
Receiving a diagnosis of trichomoniasis can be stressful and may lead to feelings of shame, anxiety, or depression. Post-treatment health checks allow healthcare providers to assess a patient’s mental well-being and offer support or referrals to mental health professionals if needed[9]. By addressing both physical and emotional health, providers can help patients navigate the challenges of an STI diagnosis and promote holistic healing.
Testing for Reinfection or Treatment Failure
Importance of Follow-up Testing
Follow-up testing is a critical component of post-treatment care for trichomoniasis. It helps determine whether the initial treatment was successful and identifies any instances of reinfection or treatment failure. The CDC recommends retesting all patients diagnosed with trichomoniasis 3 to 4 weeks after completing therapy[10]. This window allows sufficient time for the infection to clear while also detecting any persistent or newly acquired infections.
Nucleic Acid Amplification Tests (NAATs)
NAATs are the preferred method for follow-up testing due to their high sensitivity and specificity. These tests can detect the genetic material of Trichomonas vaginalis even when the parasite is present in low numbers. NAATs can be performed on various sample types, including vaginal swabs, endocervical swabs, and urine specimens[11]. The choice of sample type may depend on the patient’s gender, symptoms, and the specific NAAT platform used.
Interpreting Test Results
A positive NAAT result after treatment indicates either treatment failure or reinfection. Treatment failure can occur due to antibiotic resistance, inadequate medication adherence, or the presence of other untreated STIs that may compromise treatment effectiveness. Reinfection, on the other hand, suggests exposure to an untreated or newly infected partner[12]. In either case, a positive follow-up test necessitates further evaluation and retreatment.
A negative NAAT result after treatment suggests successful clearance of the infection. However, patients should be advised to continue practicing safer sex behaviors and to undergo regular STI screening, as a negative test does not guarantee protection against future infections.
Addressing Treatment Failure or Reinfection
If follow-up testing reveals treatment failure or reinfection, healthcare providers should promptly initiate retreatment. The CDC recommends using the same antibiotic regimen as the initial treatment, typically a single dose of oral metronidazole or tinidazole. In cases of suspected antibiotic resistance or multiple treatment failures, alternative regimens or extended courses of antibiotics may be considered.
When reinfection is suspected, it is crucial to evaluate and treat sexual partners. Providers should emphasize the importance of partner notification and concurrent treatment to break the cycle of transmission. Patients should also be counseled on the importance of abstaining from sexual activity until both they and their partners have completed treatment and are confirmed to be infection-free.
Screening for Other Sexually Transmitted Infections (STIs)
Importance of Comprehensive STI Screening
Individuals diagnosed with trichomoniasis are at a higher risk for other STIs, including chlamydia, gonorrhea, and HIV. This increased risk can be attributed to shared risk factors, such as unprotected sexual activity, and the biological interactions between trichomoniasis and other STIs. For example, the inflammation caused by trichomoniasis can increase the susceptibility to HIV acquisition[13]. Therefore, it is crucial to perform a comprehensive STI screening in patients with trichomoniasis to identify and treat any co-infections promptly.
STIs to Include in the Screening Panel
When screening patients with trichomoniasis for other STIs, healthcare providers should consider including the following infections in the testing panel:
- Chlamydia: Chlamydia trachomatis is a common bacterial STI that often co-occurs with trichomoniasis. Left untreated, chlamydia can lead to pelvic inflammatory disease and infertility.
- Gonorrhea: Like chlamydia, gonorrhea is a bacterial STI that shares risk factors with trichomoniasis. Untreated gonorrhea can cause serious reproductive health complications.
- HIV: Trichomoniasis increases the risk of HIV acquisition and transmission. HIV screening is essential for early diagnosis, treatment initiation, and prevention of further transmission[14].
- Syphilis: Syphilis is a bacterial STI that can cause severe complications if left untreated. Screening for syphilis is particularly important in high-risk populations.
Screening Methods and Frequency
STI screening methods may include NAATs, serological tests, or point-of-care rapid tests, depending on the specific infection and available resources. NAATs are the preferred method for detecting chlamydia and gonorrhea due to their high sensitivity and specificity. HIV and syphilis screening typically involve serological tests that detect antibodies against the respective pathogens.
The frequency of STI screening in patients with trichomoniasis depends on individual risk factors and the presence of symptoms. The CDC recommends that all sexually active individuals undergo annual screening for common STIs, with more frequent testing for those at higher risk[15]. In the context of trichomoniasis, healthcare providers may consider repeating STI screening 3 to 6 months after the initial diagnosis to detect any new infections.
Counseling and Risk Reduction
Comprehensive STI screening should be accompanied by patient counseling and education on risk reduction strategies. Healthcare providers should discuss the importance of consistent condom use, limiting the number of sexual partners, and regularly testing for STIs. Patients should also be informed about the potential complications of untreated STIs and the importance of prompt treatment and partner notification.
By incorporating comprehensive STI screening into the post-treatment care for trichomoniasis, healthcare providers can identify and manage co-infections, reduce the risk of complications, and promote overall sexual health and well-being.
Pelvic Inflammatory Disease (PID) Evaluation
Trichomoniasis and PID
Pelvic inflammatory disease (PID) is a serious complication of untreated STIs, particularly in women. It occurs when bacteria ascend from the vagina or cervix to the upper reproductive tract, causing infection and inflammation of the uterus, fallopian tubes, and ovaries. While chlamydia and gonorrhea are the most common causes of PID, trichomoniasis has also been associated with an increased risk of developing this condition[16]. Therefore, healthcare providers should consider evaluating patients with trichomoniasis for signs and symptoms of PID.
Symptoms and Signs of PID
The clinical presentation of PID can vary, with some women experiencing mild or nonspecific symptoms. However, common signs and symptoms of PID include:
- Lower abdominal or pelvic pain
- Abnormal vaginal discharge
- Irregular menstrual bleeding
- Dyspareunia (painful intercourse)
- Fever and chills
- Nausea and vomiting
Healthcare providers should maintain a low threshold for suspecting PID in women with trichomoniasis, especially those with persistent or recurrent symptoms following treatment.
Diagnostic Evaluation for PID
The diagnosis of PID can be challenging, as there is no single definitive test. The evaluation typically involves a combination of clinical assessment, imaging studies, and laboratory tests. Key components of the diagnostic workup for PID include:
- Pelvic examination: Healthcare providers should perform a pelvic exam to assess for cervical motion tenderness, adnexal tenderness, and uterine tenderness, which are suggestive of PID.
- Imaging studies: Transvaginal ultrasound or pelvic MRI can help visualize the reproductive organs and identify signs of inflammation, abscess formation, or tubo-ovarian complexes.
- Laboratory tests: Cervical or vaginal NAATs for chlamydia and gonorrhea, as well as tests for other STIs like trichomoniasis and HIV, can help identify the underlying cause of PID[17]. Elevated white blood cell count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels may also support the diagnosis.
Management of PID
Prompt treatment of PID is essential to prevent long-term sequelae such as infertility, ectopic pregnancy, and chronic pelvic pain. The management of PID typically involves broad-spectrum antibiotics that cover the most common causative organisms, including N. gonorrhoeae, C. trachomatis, and anaerobic bacteria. Hospitalization may be necessary for severe cases or those with complications like tubo-ovarian abscess[18].
In patients with trichomoniasis and suspected PID, healthcare providers should initiate appropriate antibiotic therapy while awaiting the results of diagnostic tests. Close follow-up is crucial to ensure clinical improvement and to monitor for any treatment failures or recurrent infections.
By incorporating PID evaluation into the post-treatment care for trichomoniasis, healthcare providers can identify and manage this potentially serious complication, ultimately improving reproductive health outcomes for affected women.
Fertility and Pregnancy Considerations
Trichomoniasis and Infertility
Trichomoniasis has been associated with infertility in both men and women. In women, untreated trichomoniasis can lead to pelvic inflammatory disease (PID), which can cause scarring and blockage of the fallopian tubes, resulting in infertility. The inflammation caused by trichomoniasis may also affect the endometrium, creating an unfavorable environment for implantation[19]. In men, trichomoniasis can cause urethritis and prostatitis, which may impact sperm quality and fertility.
Healthcare providers should discuss the potential impact of trichomoniasis on fertility with their patients, emphasizing the importance of timely treatment and follow-up care.Patients who are experiencing difficulty conceiving should be screened for trichomoniasis and other STIs as part of their infertility evaluation.
Trichomoniasis during Pregnancy
Pregnant women with trichomoniasis are at an increased risk of adverse pregnancy outcomes, including preterm delivery, low birth weight, and premature rupture of membranes. Trichomoniasis has also been associated with an increased risk of vertical transmission of HIV from mother to child[20]. Therefore, it is crucial to screen for and promptly treat trichomoniasis in pregnant women to prevent these complications.
The CDC recommends that all pregnant women at high risk for STIs, including those with multiple sexual partners or a history of STIs, be screened for trichomoniasis at the first prenatal visit. Screening should be repeated in the third trimester for women who remain at high risk[21].
Treatment Considerations during Pregnancy
The treatment of choice for trichomoniasis during pregnancy is a single 2-gram dose of oral metronidazole. This regimen is safe and effective, with no known teratogenic effects. Pregnant women should be advised to avoid alcohol consumption during treatment and for 24 to 48 hours after completing the medication to prevent a disulfiram-like reaction.
In cases of treatment failure or recurrent infections during pregnancy, healthcare providers may consider alternative regimens, such as longer courses of metronidazole or tinidazole. However, the safety and efficacy of these regimens in pregnancy have not been extensively studied.
Postpartum Care
Women who are diagnosed with trichomoniasis during pregnancy should be retested 3 to 4 weeks after completing treatment to ensure the infection has been eradicated. Postpartum screening is also recommended for women who were at high risk for STIs during pregnancy or those who had a preterm delivery.
In addition to screening and treatment, healthcare providers should provide counseling on safe sex practices, including the consistent use of condoms, to prevent reinfection and transmission of trichomoniasis and other STIs in the postpartum period.
By addressing fertility and pregnancy considerations in the context of trichomoniasis, healthcare providers can promote optimal reproductive health outcomes and prevent adverse consequences for both mothers and their children.
Promoting Sexual Health and Prevention
Patient Education and Counseling
Promoting sexual health and preventing the transmission of trichomoniasis and other STIs require a comprehensive approach that includes patient education and counseling. Healthcare providers should engage in open, non-judgmental discussions with their patients about sexual health, risk factors, and preventive strategies. Key topics to cover during these conversations include:
- The importance of consistent and correct condom use during vaginal, anal, and oral sex
- Limiting the number of sexual partners and avoiding concurrent sexual relationships
- Regularly testing for STIs, especially if engaging in high-risk behaviors or experiencing symptoms
- Knowing the signs and symptoms of trichomoniasis and other common STIs
- Seeking prompt medical attention if STI symptoms develop or after potential exposure
Healthcare providers should also emphasize the importance of partner notification and treatment to prevent reinfection and further transmission of trichomoniasis[22].
Condom Promotion and Distribution
Condoms are highly effective in preventing the transmission of trichomoniasis and other STIs when used consistently and correctly. Healthcare providers should actively promote condom use and provide patients with clear instructions on proper condom use techniques. Strategies to increase condom uptake include:
- Providing free or low-cost condoms in healthcare settings, particularly in STI clinics and reproductive health centers
- Distributing condoms through community outreach programs and partnerships with local organizations
- Offering condom demonstrations and educational materials to patients
- Addressing common barriers to condom use, such as perceived loss of pleasure or lack of negotiation skills
By normalizing condom use and making them readily available, healthcare providers can empower patients to take an active role in protecting their sexual health.
Partner Notification and Treatment
Partner notification and treatment are critical components of trichomoniasis prevention and control. When a patient is diagnosed with trichomoniasis, healthcare providers should encourage them to inform their recent sexual partners of the infection and the need for evaluation and treatment. This process can be facilitated through expedited partner therapy (EPT), where providers prescribe or dispense medications for the patient’s partners without a prior medical evaluation[23].
In some cases, patients may feel uncomfortable or unable to notify their partners directly. In these situations, healthcare providers can offer assistance through provider-led partner notification services, such as contacting partners anonymously or providing written notification materials.
Community Education and Outreach
Promoting sexual health and preventing trichomoniasis and other STIs extend beyond the healthcare setting. Community education and outreach efforts are essential for raising awareness, reducing stigma, and encouraging preventive behaviors. Healthcare providers can collaborate with local public health departments, schools, and community-based organizations to:
- Develop and disseminate culturally appropriate educational materials on trichomoniasis and sexual health
- Organize community events, such as health fairs or workshops, to provide STI education and testing services
- Advocate for comprehensive sexual health education in schools and youth-serving organizations
- Address social determinants of health that influence STI risk, such as poverty, lack of healthcare access, and gender inequality
By engaging in community education and outreach, healthcare providers can create a supportive environment that promotes sexual health and empowers individuals to make informed decisions about their well-being.
Incorporating sexual health promotion and prevention strategies into the post-treatment care for trichomoniasis is essential for reducing the burden of this infection and improving overall reproductive health outcomes. By providing patient education, promoting condom use, facilitating partner notification and treatment, and engaging in community outreach, healthcare providers can play a critical role in breaking the cycle of trichomoniasis transmission and promoting sexual health for all.
Frequently Asked Questions
No, trichomoniasis will not go away on its own without treatment. It is a sexually transmitted infection caused by a parasite that requires antibiotic therapy, usually with metronidazole or tinidazole, to be effectively treated. Untreated trichomoniasis can lead to serious complications, such as pelvic inflammatory disease and increased risk of HIV transmission.
Trichomoniasis can show up on a test as early as 5 to 28 days after exposure to the parasite. However, the incubation period can vary, and some individuals may not develop symptoms or test positive for several months after infection. It is important to get tested if you suspect you may have been exposed to trichomoniasis or if you experience any symptoms, such as unusual vaginal discharge or genital irritation.
No, you cannot get trichomoniasis from a toilet seat. The parasite that causes trichomoniasis, Trichomonas vaginalis, cannot survive long outside the human body and is primarily transmitted through sexual contact. It is important to practice safe sex, including using condoms, to reduce the risk of contracting trichomoniasis and other sexually transmitted infections.
Some people with trichomoniasis may not experience any symptoms and can have the infection for months or even years without knowing. In fact, up to 70% of individuals with trichomoniasis do not develop any noticeable signs of the infection. This is why regular STI screening is important, especially if you are sexually active or have multiple partners, to detect and treat trichomoniasis and prevent its spread.
Not necessarily. While trichomoniasis is a sexually transmitted infection, it is possible for the infection to remain dormant for an extended period. This means that you or your partner could have contracted the infection from a previous sexual encounter and only recently developed symptoms or tested positive. It is essential to have an open and honest conversation with your partner and healthcare provider to determine the best course of action and to address any concerns about infidelity or trust in your relationship.
While trichomoniasis is most commonly transmitted through vaginal sex, it is possible, although less common, to contract the infection through oral or anal sex. The parasite that causes trichomoniasis can infect the genital area, including the vulva, vagina, penis, and urethra. If the parasite comes into contact with the mouth or rectum during oral or anal sex, there is a risk of transmission. Using dental dams or condoms during oral and anal sex can help reduce the risk of contracting trichomoniasis and other STIs.
Yes, untreated trichomoniasis can potentially lead to infertility, particularly in women. The infection can cause inflammation of the reproductive tract, leading to pelvic inflammatory disease (PID). PID can result in scarring and blockage of the fallopian tubes, making it difficult for fertilization to occur or increasing the risk of ectopic pregnancy. Prompt diagnosis and treatment of trichomoniasis are essential to prevent these long-term complications and preserve fertility.
Yes, it is possible to get reinfected with trichomoniasis after treatment. If your sexual partner has not been treated or if you have sex with a new partner who has the infection, you can contract trichomoniasis again. To prevent reinfection, it is crucial that all sexual partners receive treatment and that you abstain from sexual activity until treatment is complete and symptoms have resolved. Additionally, practicing safe sex by using condoms consistently can help reduce the risk of reinfection and transmission of trichomoniasis and other STIs.
Reference list
- Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR, Secor WE, Sobel JD, Workowski KA. A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections. Clin Infect Dis. 2015 Dec 15;61 Suppl 8(Suppl 8):S837-48.
- Sherrard J, Ison C, Moody J, Wainwright E, Wilson J, Sullivan A. United Kingdom National Guideline on the Management of Trichomonas vaginalis 2014. Int J STD AIDS. 2014 Jul;25(8):541-9.
- Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.
- Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015 Aug 5;15:307.
- Van Der Pol B. Clinical and Laboratory Testing for Trichomonas vaginalis Infection. J Clin Microbiol. 2016 Jan;54(1):7-12.
- Schwebke JR, Gaydos CA, Davis T, Marrazzo J, Furgerson D, Taylor SN, Smith B, Bachmann LH, Ackerman R, Spurrell T, Ferris DG, Burnham CA, Reno H, Lebed J, Eisenberg D, Kerndt P, Philip SS, Jordan J, Quigley N. Clinical Evaluation of the Cepheid Xpert TV Assay for Detection of Trichomonas vaginalis with Prospectively Collected Specimens from Men and Women. J Clin Microbiol. 2018 Feb 22;56(3):e01674-17.
- Gaydos CA, Klausner JD, Pai NP, Kelly H, Coltart C, Peeling RW. Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. Sex Transm Infect. 2017 Dec;93(S4):S31-S35.
- Howe K, Kissinger PJ. Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis. Sex Transm Dis. 2017 Jan;44(1):29-34.
- Muzny CA, Schwebke JR. Pathogenesis of Trichomonas vaginalis infections in women: a narrative review. Sex Transm Infect. 2022 Feb;98(1):21-27.
- Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, Kerani RP, Mettenbrink CJ, Pathela P, Schwebke JR, Secor WE, Workowski KA, Davis D, Braxton J, Weinstock HS. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis. 2012 Jun;18(6):939-43.
- Schwebke JR, Hobbs MM, Taylor SN, Sena AC, Catania MG, Weinbaum BS, Johnson AD, Getman DK, Gaydos CA. Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial. J Clin Microbiol. 2011 Dec;49(12):4106-11.
- Kissinger P, Muzny CA, Mena LA, Lillis RA, Schwebke JR, Beauchamps L, Taylor SN, Schmidt N, Myers L, Augostini P, Secor WE, Bolan G, Bachmann LH, Hobbs MM. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Nov;18(11):1251-1259.
- Silver BJ, Guy RJ, Kaldor JM, Jamil MS, Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014 Jun;41(6):369-76.
- Carter JE, Whithaus KC. Neonatal respiratory tract involvement by Trichomonas vaginalis: a case report and review of the literature. Am J Trop Med Hyg. 2008 Jan;78(1):17-9.
- Coleman JS, Gaydos CA, Witter F. Trichomonas vaginalis vaginitis in obstetrics and gynecology practice: new concepts and controversies. Obstet Gynecol Surv. 2013 Jan;68(1):43-50.
- Mann JR, McDermott S, Barnes TL, Hardin J, Bao H, Zhou L. Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol. 2009 Dec;19(12):891-9.
- Mielczarek E, Blaszkowska J. Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure. Infection. 2016 Aug;44(4):447-58.
- Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C; Partners in Prevention HSV/HIV Transmission Study Team. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012 Feb 1;205(3):358-65.
- Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998 Apr;11(2):300-17.
- Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.
- Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187.
- Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, Clark A, Malinski C, Helmers JR, Thomas KK, Holmes KK. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005 Feb 17;352(7):676-85.
